Colin Broom M.D.
Net Worth
Last updated:
What is Colin Broom M.D. net worth?
The estimated net worth of Dr. Colin Broom M.D. is at least $328,821 as of 2 Aug 2022. He has earned $8,821 from insider trading and has received compensation worth at least $320,000 in Nabriva Therapeutics plc.
What is the salary of Colin Broom M.D.?
Dr. Colin Broom M.D. salary is $40,000 per year as Director in Nabriva Therapeutics plc.
How old is Colin Broom M.D.?
Dr. Colin Broom M.D. is 69 years old, born in 1956.
What stocks does Colin Broom M.D. currently own?
As insider, Dr. Colin Broom M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Nabriva Therapeutics plc (NBRV) | Director | 36,523 | $0 | $0 |
What does Nabriva Therapeutics plc do?
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Colin Broom M.D. insider trading
Nabriva Therapeutics plc
Dr. Colin Broom M.D. has made 4 insider trades between 2017-2022, according to the Form 4 filled with the SEC. Most recently he sold 5,339 units of NBRV stock worth $1,014 on 2 Aug 2022.
The largest trade he's ever made was exercising 33,750 units of NBRV stock on 19 Aug 2019. As of 2 Aug 2022 he still owns at least 36,523 units of NBRV stock.
Nabriva Therapeutics key executives
Nabriva Therapeutics plc executives and other stock owners filed with the SEC:
- Dr. Colin Broom M.D. (69) Director
- Dr. Steven P. Gelone Pharm. D (57) Pres, Chief Operating Officer & Director
- Mr. Theodore R. Schroeder (70) Chief Executive Officer & Director